When times got tough, the biopharma industry hit the Zoom button and kept things moving at a multibillion-dollar clip
Don’t ever underestimate biopharma’s ability to grab ahold of an opportunity, even if they can’t close a deal with a handshake.
While retail and other industries struggle to survive a vicious downturn brought on by the pandemic, biopharma continues to make fresh gains — or stay on an elevated track — on most dealmaking fronts. And this new set of charts from DealForma chief Chris Dokomajilar underscores the heightened level of activity this past spring.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.